Struggles include finding the right medication and medication side effects
Announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year
Greatest decline in incident stimulant and anxiolytic/sedative-hypnotic medications was in quarter 2 of 2020
Drug shows promise in clearing brain plaques believed to play a role in Alzheimer disease
Amyloid-related imaging abnormalities-edema seen on brain MRI most common adverse event in participants receiving high-dose aducanumab
Concomitant use of central nervous system-depressant drugs listed for 58.4 percent of off-label gabapentin visits
Grounds insufficient to offer aducanumab for moderate, advanced Alzheimer dementia or patients without biomarker evidence of brain ß-amyloid
Phase 1 trial will include 16 patients ages 60 to 85 years who have early, symptomatic Alzheimer disease but are otherwise in good health
Combining varenicline with nicotine patch, extending treatment from 12 to 24 weeks did not increase smoking cessation rates
However, most common product type and intent of use associated with these visits vary by age